TARSUS PHARMACEUTICALS INC (TARS) Fundamental Analysis & Valuation

NASDAQ:TARS • US87650L1035

Current stock price

68.9 USD
+0.94 (+1.38%)
At close:
68 USD
-0.9 (-1.31%)
After Hours:

This TARS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. TARS Profitability Analysis

1.1 Basic Checks

  • TARS had negative earnings in the past year.
  • In the past year TARS has reported a negative cash flow from operations.
  • TARS had negative earnings in each of the past 5 years.
  • TARS had negative operating cash flow in 4 of the past 5 years.
TARS Yearly Net Income VS EBIT VS OCF VS FCFTARS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -11.81%, TARS is in the better half of the industry, outperforming 64.58% of the companies in the same industry.
  • The Return On Equity of TARS (-19.34%) is better than 68.23% of its industry peers.
Industry RankSector Rank
ROA -11.81%
ROE -19.34%
ROIC N/A
ROA(3y)-31.22%
ROA(5y)-25.73%
ROE(3y)-46.6%
ROE(5y)-36.05%
ROIC(3y)N/A
ROIC(5y)N/A
TARS Yearly ROA, ROE, ROICTARS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • TARS has a better Gross Margin (93.20%) than 95.31% of its industry peers.
  • TARS's Gross Margin has been stable in the last couple of years.
  • TARS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.08%
GM growth 5YN/A
TARS Yearly Profit, Operating, Gross MarginsTARS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TARS Health Analysis

2.1 Basic Checks

  • TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TARS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TARS has more shares outstanding
  • The debt/assets ratio for TARS has been reduced compared to a year ago.
TARS Yearly Shares OutstandingTARS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
TARS Yearly Total Debt VS Total AssetsTARS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • TARS has an Altman-Z score of 8.08. This indicates that TARS is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 8.08, TARS belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
  • TARS has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
  • TARS has a Debt to Equity ratio (0.21) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 8.08
ROIC/WACCN/A
WACC9.51%
TARS Yearly LT Debt VS Equity VS FCFTARS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • TARS has a Current Ratio of 3.85. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
  • TARS has a Current ratio (3.85) which is in line with its industry peers.
  • A Quick Ratio of 3.82 indicates that TARS has no problem at all paying its short term obligations.
  • TARS has a Quick ratio of 3.82. This is in the better half of the industry: TARS outperforms 60.42% of its industry peers.
Industry RankSector Rank
Current Ratio 3.85
Quick Ratio 3.82
TARS Yearly Current Assets VS Current LiabilitesTARS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TARS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 47.74% over the past year.
  • The Revenue has grown by 146.71% in the past year. This is a very strong growth!
  • Measured over the past years, TARS shows a very strong growth in Revenue. The Revenue has been growing by 159.53% on average per year.
EPS 1Y (TTM)47.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)146.71%
Revenue growth 3Y159.53%
Revenue growth 5YN/A
Sales Q2Q%128.39%

3.2 Future

  • TARS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.08% yearly.
  • TARS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.47% yearly.
EPS Next Y143.62%
EPS Next 2Y101.61%
EPS Next 3Y78.13%
EPS Next 5Y48.08%
Revenue Next Year55.65%
Revenue Next 2Y40.3%
Revenue Next 3Y32.79%
Revenue Next 5Y24.47%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TARS Yearly Revenue VS EstimatesTARS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
TARS Yearly EPS VS EstimatesTARS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. TARS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TARS. In the last year negative earnings were reported.
  • TARS is valuated quite expensively with a Price/Forward Earnings ratio of 97.51.
  • 69.27% of the companies in the same industry are more expensive than TARS, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, TARS is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 97.51
TARS Price Earnings VS Forward Price EarningsTARS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARS Per share dataTARS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • TARS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • TARS's earnings are expected to grow with 78.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101.61%
EPS Next 3Y78.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TARS Dividend Analysis

5.1 Amount

  • No dividends for TARS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TARS Fundamentals: All Metrics, Ratios and Statistics

TARSUS PHARMACEUTICALS INC

NASDAQ:TARS (3/16/2026, 8:00:00 PM)

After market: 68 -0.9 (-1.31%)

68.9

+0.94 (+1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-23
Earnings (Next)04-29
Inst Owners105.45%
Inst Owner Change-1.06%
Ins Owners3.05%
Ins Owner Change-1.07%
Market Cap2.93B
Revenue(TTM)451.36M
Net Income(TTM)-66.42M
Analysts88
Price Target93.2 (35.27%)
Short Float %13.2%
Short Ratio8.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.01%
Min EPS beat(2)-106.09%
Max EPS beat(2)16.07%
EPS beat(4)2
Avg EPS beat(4)-23.42%
Min EPS beat(4)-106.09%
Max EPS beat(4)16.07%
EPS beat(8)6
Avg EPS beat(8)-1.25%
EPS beat(12)9
Avg EPS beat(12)0.52%
EPS beat(16)12
Avg EPS beat(16)6.71%
Revenue beat(2)2
Avg Revenue beat(2)1.92%
Min Revenue beat(2)0.99%
Max Revenue beat(2)2.85%
Revenue beat(4)4
Avg Revenue beat(4)3.75%
Min Revenue beat(4)0.99%
Max Revenue beat(4)5.98%
Revenue beat(8)8
Avg Revenue beat(8)14.59%
Revenue beat(12)10
Avg Revenue beat(12)40.02%
Revenue beat(16)11
Avg Revenue beat(16)19.85%
PT rev (1m)5.16%
PT rev (3m)7.18%
EPS NQ rev (1m)-2682.88%
EPS NQ rev (3m)-545.26%
EPS NY rev (1m)-60.95%
EPS NY rev (3m)-61.24%
Revenue NQ rev (1m)1.37%
Revenue NQ rev (3m)1.37%
Revenue NY rev (1m)1.23%
Revenue NY rev (3m)1.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 97.51
P/S 6.5
P/FCF N/A
P/OCF N/A
P/B 8.54
P/tB 8.73
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)0.71
Fwd EY1.03%
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS10.61
BVpS8.07
TBVpS7.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.81%
ROE -19.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.2%
FCFM N/A
ROA(3y)-31.22%
ROA(5y)-25.73%
ROE(3y)-46.6%
ROE(5y)-36.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.08%
GM growth 5YN/A
F-Score5
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 542.9%
Cap/Sales 2.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.85
Quick Ratio 3.82
Altman-Z 8.08
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)568.78%
Cap/Depr(5y)410.24%
Cap/Sales(3y)12.44%
Cap/Sales(5y)8.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y143.62%
EPS Next 2Y101.61%
EPS Next 3Y78.13%
EPS Next 5Y48.08%
Revenue 1Y (TTM)146.71%
Revenue growth 3Y159.53%
Revenue growth 5YN/A
Sales Q2Q%128.39%
Revenue Next Year55.65%
Revenue Next 2Y40.3%
Revenue Next 3Y32.79%
Revenue Next 5Y24.47%
EBIT growth 1Y41.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.28%
EBIT Next 3Y79.44%
EBIT Next 5Y67.7%
FCF growth 1Y75.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85%
OCF growth 3YN/A
OCF growth 5YN/A

TARSUS PHARMACEUTICALS INC / TARS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TARSUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 4 / 10 to TARS.


What is the valuation status for TARS stock?

ChartMill assigns a valuation rating of 2 / 10 to TARSUS PHARMACEUTICALS INC (TARS). This can be considered as Overvalued.


Can you provide the profitability details for TARSUS PHARMACEUTICALS INC?

TARSUS PHARMACEUTICALS INC (TARS) has a profitability rating of 2 / 10.